Jemma Arakelyan: Insights on the trial of Balstilimab + Botensilimab in Metastatic NSCLC
Jemma Arakelyan, Medical Oncologist, CEO at the Institute of Cancer and Crisis, shared a post on LinkedIn by Immune Oncology Research Institute, adding:
“Dr. Samvel Bardakhchyan shares insights about the ongoing clinical trial at The Immune Oncology Research Institute in collaboration with Agenus. This groundbreaking initiative focuses on developing novel immunotherapies that have the potential to transform outcomes for patients with non-small cell lung cancer.”
Quoting Immune Oncology Research Institute‘s post:
“Assessment of the safety and efficacy of balstilimab in combination with botensilimab for the treatment of non-small cell lung cancer (IMMONC0008) – NCT06322108
IMMONC, in collaboration with Agenus, has launched a new trial, which will assess the safety and efficacy of the anti-CTLA-4 agent (botensilimab in combination with anti-PD-1 antibody balstilimab in the frontline treatment of metastatic non-small cell lung cancer (NSCLC).
The study will enroll participants with a histologically confirmed diagnosis of metastatic NSCLC and without targetable EGFR mutation or ALK rearrangement, while excluding those with untreated brain metastases or oligometastatic disease lacking targetable lesions.
The total estimated maximum time of study participation for each patient is approximately 49 months across 3 periods.
The Principal Investigator of the trial is Dr. Samvel Bardakhchyan, the study team includes Prof. Gevorg Tamamyan Dr. Davit Zohrabyan , Dr. Liana Safaryan, and Dr. Amalya Sargsyan.”
Learn more about the latest research in immunotherapy for NSCLC on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023